Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
PaperCitations, authors & open-access status
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 124 citations, 2023 year and hybrid oa status.
124
Citations
2023
Year
hybrid
OA Status